Mylan (NASDAQ:MYL) was the recipient of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 21,122,199 shares, a decrease of 12.6% from the November 15th total of 24,179,923 shares. Approximately 4.2% of the company’s stock are sold short. Based on an average daily volume of 5,331,193 shares, the days-to-cover ratio is presently 4.0 days.

Several institutional investors have recently added to or reduced their stakes in the company. Sei Investments Co. raised its position in Mylan by 24.2% in the second quarter. Sei Investments Co. now owns 17,233 shares of the company’s stock worth $669,000 after acquiring an additional 3,363 shares in the last quarter. Global X Management Co. LLC raised its position in Mylan by 59.2% in the second quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock worth $186,000 after acquiring an additional 1,786 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in Mylan by 2.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 1,602,389 shares of the company’s stock worth $62,205,000 after acquiring an additional 33,510 shares in the last quarter. Advisors Asset Management Inc. raised its position in Mylan by 5.7% in the second quarter. Advisors Asset Management Inc. now owns 73,170 shares of the company’s stock worth $2,840,000 after acquiring an additional 3,965 shares in the last quarter. Finally, State of Wisconsin Investment Board raised its position in Mylan by 50.5% in the second quarter. State of Wisconsin Investment Board now owns 1,115,968 shares of the company’s stock worth $43,322,000 after acquiring an additional 374,550 shares in the last quarter. Institutional investors and hedge funds own 75.04% of the company’s stock.

Shares of Mylan (NASDAQ:MYL) opened at $39.53 on Thursday. Mylan has a 52 week low of $29.39 and a 52 week high of $45.87. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $21,183.87, a P/E ratio of 8.40, a PEG ratio of 2.16 and a beta of 1.38.

Mylan (NASDAQ:MYL) last released its quarterly earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The company had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $3.09 billion. During the same quarter last year, the company earned $1.38 EPS. Mylan’s revenue for the quarter was down 2.3% compared to the same quarter last year. research analysts forecast that Mylan will post 4.56 EPS for the current fiscal year.

MYL has been the subject of several research analyst reports. ValuEngine raised Mylan from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. BMO Capital Markets reissued a “buy” rating and issued a $45.00 price objective on shares of Mylan in a report on Friday, September 29th. Mizuho reissued a “buy” rating and issued a $37.00 price objective (down from $53.00) on shares of Mylan in a report on Sunday, August 20th. Citigroup raised Mylan from a “neutral” rating to a “buy” rating and increased their price objective for the company from $36.00 to $42.00 in a report on Wednesday, August 16th. Finally, BTIG Research increased their price objective on Mylan from $42.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $42.41.

COPYRIGHT VIOLATION WARNING: This story was reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/14/mylan-myl-short-interest-down-12-6-in-november.html.

About Mylan

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.